16-Gene Recurrence Score for High-Risk RCC Offers Prognostic Value

Analysis from a phase III trial confirmed the prognostic value of a 16-gene recurrence score in patients with high-risk renal cell carcinoma undergoing adjuvant sunitinib therapy.

Source: CancerNetwork - June 9, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Conferences/ASCO Renal Cell Carcinoma News Source Type: news